H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Daré Bioscience (DARE – Research Report) today and set a price target of $12.00.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Daré Bioscience’s strategic approach and market potential. The company’s decision to introduce its sildenafil cream through a compounding pharmacy partner is seen as a bold and innovative move that could significantly accelerate revenue growth. This strategy allows Daré to bypass the traditional FDA-approval process temporarily, enabling quicker market access while still pursuing formal approval for long-term benefits.
Furthermore, the evolving landscape of the compounding pharmacy business, with its focus on subscription models and expanding product offerings, presents an attractive opportunity for Daré. The company’s pipeline, including sildenafil cream, aligns well with the growth strategies of these pharmacies, making Daré an appealing partner. This partnership can leverage the marketing expertise of compounding pharmacies, reducing the burden on Daré and potentially enhancing their market reach, especially once FDA approval is secured, allowing them to target the broader women’s health market effectively.